Adaptor Proteins, Vesicular Transport; Antiviral Agents; Benzopyrans; Cell Line; Chikungunya Fever; Chikungunya virus; Cytokines; DNA Replication; Dengue; Dengue Virus; Drug Discovery; Gene Editing; Host-Pathogen Interactions; Humans; Immune Evasion; Immunity, Innate; Interferon Regulatory Factor-3; Interferon Type I; Leukocytes, Mononuclear; Thiadiazoles; Virus Replication; Zika Virus
The ongoing concurrent outbreaks of Zika, Chikungunya, and dengue viruses in Latin America and the Caribbean highlight the need for development of broad-spectrum antiviral treatments. The type I interferon (IFN) system has evolved in vertebrates to generate tissue responses that actively block replication of multiple known and potentially zoonotic viruses. As such, its control and activation through pharmacological agents may represent a novel therapeutic strategy for simultaneously impairing growth of multiple virus types and rendering host populations resistant to virus spread. In light of this strategy's potential, we undertook a screen to identify novel interferon-activating small molecules. Here, we describe 1-(2-fluorophenyl)-2-(5-isopropyl-1,3,4-thiadiazol-2-yl)-1,2-dihydrochromeno[2,3-
Earle A. Chiles Research Institute
Pryke, Kara M; Abraham, Jinu; Sali, Tina M; Gall, Bryan J; Archer, Iris; Liu, Andrew; Bambina, Shelly; Baird, Jason R; Gough, Michael J.; Chakhtoura, Marita; Haddad, Elias K; Kirby, Ilsa T; Nilsen, Aaron; Streblow, Daniel N; Hirsch, Alec J; Smith, Jessica L; and DeFilippis, Victor R, "A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses." (2017). Articles, Abstracts, and Reports. 1555.